The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Sep 2015
Meta AnalysisCardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. ⋯ GlaxoSmithKline.